---
schema_version: "secwatch.filing_event.v1"
accession: "0001339970-26-000065"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2026-09-24T11:47:35+00:00"
generated_at: "2026-09-24T11:55:17.888266+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma reaches FDA alignment on Phase 3 protocol for efzofitimod in pulmonary sarcoidosis

## Summary
- Study to start Q4 2026; global, randomized, double-blind, placebo-controlled, 54-week trial.
- Two parallel cohorts: 5.0 mg/kg efzofitimod vs placebo IV every 3 weeks for 17 doses; up to 372 patients.
- Primary endpoint: change from baseline FVC at week 48; key secondary: KSQ-Lung score change at week 48.
- Design supported by EFZO-FIT subgroup data showing clinically meaningful FVC and patient-reported improvements.
- Company expects to need additional capital via equity/debt, grants, collaborations, or licensing for study.

## SEC filing metadata
- accession: 0001339970-26-000065
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2026-09-24T11:47:35+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000065/0001339970-26-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000065/atyr-20260924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001339970-26-000065
- JSON: https://secwatch.observer/filing/0001339970-26-000065.json
- Plain text: https://secwatch.observer/filing/0001339970-26-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.